Form 4: PTC Therapeutics Director Transfers Shares to Irrevocable Trust
SEC Form 4 Filing
Director David P. Southwell transferred 1,650 shares of PTC Therapeutics common stock to an irrevocable trust on May 8, 2024.
Summary
- On May 8, 2024, David P. Southwell, a director of PTC Therapeutics, Inc., transferred 1,650 shares of common stock to The David P. Southwell Irrevocable Trust of 2024.
- The transfer was made for no consideration.
- Following the transaction, Southwell directly owns 12,850 shares of PTC Therapeutics common stock.
- The trust, for which Southwell and his family are beneficiaries, has an independent trustee with investment control over the transferred shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a share transfer to a trust, which is neutral in sentiment.
Industry Context
This is a routine disclosure related to insider transactions and doesn't necessarily reflect a change in the company's outlook or performance. It is a common estate planning strategy.
Key Dates
| Date | Description |
|---|---|
| 05/08/2024 | Date of the share transfer to the irrevocable trust |
| 05/10/2024 | Date of signature by Attorney-in-Fact |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.